Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Mol Cancer Res. 2018 May 2;16(7):1161–1171. doi: 10.1158/1541-7786.MCR-18-0042

Figure 3. Impact of USP22 knockdown on sensitivity of tumorspheres to cisplatin treatment.

Figure 3

A. Western Blot analysis of USP22, CD133 and H2Bub1 in the parental tumorsphere cells and tumorsphere cells that survived a 72h of 1, 2, 4 and 6 μM cisplatin treatment, indicating survived tumorsphere cells have elevated USP22 protein with the increase of cisplatin concentration. B. Cytotoxic effects of cisplatin in GFP-CTRL and USP22-KD cells. C. Flow cytometry analysis of apoptosis (upper panel) and quantitative analysis of induced apoptosis (lower panel) in GFP-CTRL and USP22-KD cells cisplatin treatment (**P < 0.01, compared with control), demonstrating USP22 knockdown significantly sensitized CICs to cisplatin.